4SCAR19 + 4SCAR30

4SCAR19 + 4SCAR30 is a **combination cellular immunotherapy** composed of two fourth-generation chimeric antigen receptor T cell (CAR-T) products: **4SCAR19** (targeting CD19) and **4SCAR30** (targeting CD30). This combination is designed to treat **relapsed or refractory B-cell malignancies**—particularly B-cell lymphoma—by simultaneously targeting multiple tumor-associated antigens to reduce the likelihood of antigen escape and improve the likelihood of remission. Both CAR-T products incorporate advanced safety and efficacy features, notably a lentiviral-based CAR with dual costimulatory signals (CD28/CD27) and an inducible caspase 9 suicide switch for enhanced control and reduced toxicity. This approach leverages the precision of antigen profile-guided therapy and the synergistic effects of dual-target antigen recognition to increase remission rates and improve durability of response in patients otherwise resistant to standard therapies[1][3][7].